DiaMedica Therapeutics Inc. (DMAC) Institutional Ownership

Ownership Summary

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) appears in 97 institutional 13F filings for the quarter ending March 2026.

• These investors held 21.7% of outstanding shares in March 2026, down from 26.0% in December 2025.
• Their total shares held in DMAC increased 5.18% quarter over quarter, and separately, investors owning DiaMedica Therapeutics increased 67.24% from a year ago.
• Of these 97 holders, 47 added to their stakes in DiaMedica Therapeutics, 25 trimmed positions, and 25 made no changes.
• In total, institutional investors held 11.7Mn shares in DiaMedica Therapeutics as of March 2026, up by 576.33K shares quarter on quarter, and up 2.03Mn shares year over year.
• COOPERMAN LEON G leads ownership in DMAC with 2.02Mn shares as of March 31, 2026, equal to 3.76% of outstanding shares.
• The largest buyers of DiaMedica Therapeutics for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (333.46K), VANGUARD PORTFOLIO MANAGEMENT LLC (203.46K), VANGUARD FIDUCIARY TRUST CO (187.72K), MILLENNIUM MANAGEMENT LLC (167.03K), OSAIC HOLDINGS, INC. (72.7K).
• The largest sales of DMAC for the quarter ending March 2026 came from Morgan Stanley (442.19K), Goldman Sachs Group Inc (199.49K), Barclays Plc (46.42K), BlackRock, Inc. (44.71K), World Investment Advisors (36.98K).
• DiaMedica Therapeutics's 10 largest shareholders as of March 2026 include COOPERMAN LEON G (2.02Mn), BlackRock, Inc. (1.86Mn), MILLENNIUM MANAGEMENT LLC (935.59K), PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE (875.0K), GEODE CAPITAL MANAGEMENT, LLC (780.52K), State Street Corp (644.21K), FIRST MANHATTAN CO. LLC. (455.0K), Bleichroeder LP (382.32K), Northern Trust Corp (338.53K), VANGUARD CAPITAL MANAGEMENT LLC (333.46K) per Business Quant data.